Posted on 07/26/2006 2:25:15 PM PDT by neverdem
Reversing a strategy that had drawn criticism from doctors, Pfizer says that it will apply for approval to sell a promising new heart treatment as a standalone pill rather than only in combination with Lipitor, Pfizers best-selling cholesterol treatment.
The new drug, torcetrapib, is still being tested in clinical trials and is at least 18 months from federal approval.
But cardiologists say it has the potential to become a significant new treatment for heart disease.
Clinical trials show that torcetrapib substantially raises the levels of so-called good cholesterol, a novel approach to preventing heart attacks and strokes.
Wall Street analysts predict that it could become a blockbuster medicine, with sales of several billion dollars annually.
Previously, Pfizer had said it would sell torcetrapib only in combination with Lipitor, one of several medicines called statins that lower levels of LDL, or bad cholesterol. Cholesterol-reducing medicines are the largest prescription drug category, with worldwide sales of $32 billion last year.
By offering torcetrapib only in a combination pill, Pfizer would have forced patients taking other statins like Zocor, from Merck to switch to Lipitor if they wanted torcetrapibs benefits.
In an interview last year, Dr. John L. LaMattina, Pfizers top scientist, defended the companys plans, saying that the costs of testing torcetrapib alongside every statin would be prohibitive. Already, Pfizer says it is spending $800 million to develop torcetrapib. Pfizer is the worlds largest drug maker, with sales of $51 billion and a profit of $8 billion last year.
But Pfizers plan angered cardiologists, who said the company appeared to be putting its profits ahead of patients health. Not all patients can easily switch from one statin to another, and some patients cannot take statins at all. In June 2005, an article in The New England Journal of Medicine...
(Excerpt) Read more at nytimes.com ...
And why, precisely, would Pfizer have to pay for those studies?? Seems to me that the manufacturers of those "other statins" would be the ones verifying the performance of THEIR statins vis-a-vis the new HDL-raising drug.
Nothing the Pharmaceutical Industry does in regard to marketing surprises me anymore. I would like to see the outcomes data on this drug (not just the cholesterol levels and 'decreasing plaque' size but a decrease in heart attacks, strokes or deaths) before adding this to an already numerically large and expensive medication regimen that cardiac patients are prescribed...
For Example: Beta Blockers, ACE Inhibitors, Aspirin, a Statin, maybe nitroglycerin, plavix, and other medications for their other non-cardica health problems...
The other medications/statins have NO incentive to pay for those studies...they already have a market share and what if their drug had similar outcomes (or worse, faired poorly) against the new drug)...it is very difficult to get head to head studies performed against 'established' medications...
But the point is that the HDL drug would probably always be taken IN ADDITION TO a statin drug. If they don't test their statin in combinatin use with the HDL drug, then they will lose market share vs. Lipitor. Seems to me that if they want to retain market share, they'd do the testing.
Blah, blah, blah!
When they do a study and put these "wonder drugs" up against NIACIN I might change my mind.
Niacin bested them in in The Coronary Drug Project 20 years ago and would do it again today.
More smoke and mirrors to keep the patents current./flame suit on
1: J Am Coll Cardiol. 1986 Dec;8(6):1245-55.
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin.
Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, Friedewald W.
The Coronary Drug Project was conducted between 1966 and 1975 to assess the long-term efficacy and safety of five lipid-influencing drugs in 8,341 men aged 30 to 64 years with electrocardiogram-documented previous myocardial infarction. The two estrogen regimens and dextrothyroxine were discontinued early because of adverse effects. No evidence of efficacy was found for the clofibrate treatment. Niacin treatment showed modest benefit in decreasing definite nonfatal recurrent myocardial infarction but did not decrease total mortality. With a mean follow-up of 15 years, nearly 9 years after termination of the trial, mortality from all causes in each of the drug groups, except for niacin, was similar to that in the placebo group. Mortality in the niacin group was 11% lower than in the placebo group (52.0 versus 58.2%; p = 0.0004). This late benefit of niacin, occurring after discontinuation of the drug, may be a result of a translation into a mortality benefit over subsequent years of the early favorable effect of niacin in decreasing nonfatal reinfarction or a result of the cholesterol-lowering effect of niacin, or both.
PMID: 3782631 [PubMed - indexed for MEDLINE]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=3782631&query_hl=9&itool=pubmed_docsum
Thanks for the link.
From National Institute of Health Policosanol. You can buy off the web for dirt cheap. A typical 20mg 60 pills go for less than $20 that lasts for 2 months.
Disclaimer: I got no connection to the site...
Also search policosanol articles on the same site, you'll find a lot of good info. The only thing I do, changed my diet (no longer stuff 'til you drop :), walked and exercised regulary, and I have been on it for 4 years, my total down from 270s to 170s. I can't speak enough good of this stuff. I recommend if anyone interested, talk and discuss with your physician.
Not quite. Read my post #9. Policosanol is natural like "alcohol" and it doesn't hurt your liver like any other prescribed drugs. I agreed that the phamarceutical companies are not very truthful about "cholesterol" control.
Gee... bad grammar.
See post #6
To heal a wound, turn up the voltage
Diabetes study finds children at higher risk - Study strengthens warning obesity could shorten life
FReepmail me if you want on or off my health and science ping list.
thanks for the links...
oxcart, what is your recommended dose per day?
Lipitor is some of the NASTIEST stuff around. I took it for 3 months and one of my ankles and foot started swelling and HURTING. I've been off the stuff a year and it looks like the swelling is permanent.
Not if they can use political influence to force Pfizer to pay for it.
Five months later:
http://www.freerepublic.com/focus/f-news/1747738/posts
Pfizer Ends Studies on Drug for Treating Heart Disease
NY Times ^ | December 3, 2006 | ALEX BERENSON
Posted on 12/03/2006 12:46:25 AM PST by neverdem
Pfizer announced last night that it had discontinued research on its most important experimental drug, a treatment for heart disease. The decision is a stunning development that is likely to seriously damage the companys prospects through the next decades.
Preliminary research found that the drug, torcetrapib, appeared to be linked with deaths and heart problems in the patients who were taking it.
For people with heart disease, Pfizers decision to stop the trial represents the failure of a drug that many cardiologists had viewed as a potentially major advance in efforts to reduce heart attacks and strokes.
Torcetrapib is designed to raise levels of so-called good cholesterol. It was to be used in combination with older drugs called statins, like Lipitor and Zocor, which reduce so-called bad cholesterol.
As recently as Thursday [11/31/06--note this article was dated 12/3/06], Pfizer executives had hailed the drug at a meeting with investors and analysts at the companys research center in Groton, Conn.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.